pharmaphorum December 24, 2025
Sanofi’s last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5 billion agreement to buy vaccine developer Dynavax.
The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which already markets an adult vaccine that protects against hepatitis B virus (HBV), called Heplisav-B, sales of which came in at around $95 million in the third quarter.
First approved by the FDA in 2017, Heplisav-B has steadily gained momentum, thanks to a two-dose regimen delivered within one month, which differentiates it from rival shots like GSK’s Engerix-B and MSD’s Recombivax HB, which require three doses over six months.
Dynavax has said its shot is leading the market for...
Today's Sponsors
Today's Sponsor